Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy
- 1 January 2000
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 59 (2) , 171-175
- https://doi.org/10.1023/a:1006394317282
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Immunohistochemical Study on the Expression of c-erbB-2 Oncoprotein in Breast CancerOncology, 1994
- Amplification of c-erbB-2, int-2 and c-myc Genes in Node-Negative Breast Carcinomas: Relationship to PrognosisActa Oncologica, 1993
- Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancerBritish Journal of Cancer, 1992
- The long term prognostic significance of c-erbB-2 in primary breast cancerBritish Journal of Cancer, 1991
- c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodesBritish Journal of Cancer, 1991
- Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or MoreJNCI Journal of the National Cancer Institute, 1990
- An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancerBritish Journal of Cancer, 1989
- HER-2/neu oncogene protein and prognosis in breast cancer.Journal of Clinical Oncology, 1989
- An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinomaBritish Journal of Cancer, 1988
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987